Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Monday, February 27, 2017

E-cigarettes associated with CV risk factors

How is your doctor getting you the benefits of nicotine post-stroke? Assuming that your doctor knows anything about using nicotine for stroke recovery.

Nicotine Holds Promise for Stronger Stroke Recovery


Nicotine Patch Appears To Help Mild Cognitive Loss


Can nicotine protect the aging brain?
Habitual electronic cigarette use was associated with a shift in cardiac autonomic balance toward sympathetic predominance and increased oxidative stress, both indicators of CV risk, according to recently published findings.
“Although tobacco cigarettes are widely recognized as the most common preventable cause of [CVD] in the world, virtually nothing is known about the [CV] risks of e-cigarettes,” Holly R. Middlekauff, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues wrote. “Rather than wait decades for epidemiological data in habitual e-cigarette users to become available, we reasoned that investigations into several of the known mechanisms by which tobacco cigarettes increase [CV] risk would provide insights in the health risk of e-cigarettes.”
Habitual e-cigarette users (n = 23) and nonuser controls (n = 19) aged 21 to 45 years, with no current tobacco smoking and no known health problems or prescription medications, were studied. The participants (35% women; 35% white; mean age, 27.6 years) were measured for heart rate variability components and oxidative stress.
The high-frequency component (0.15-0.4 Hz), an indicator of vagal activity, was decreased in e-cigarette users compared with nonusers (mean, 46.5 normalized units [nu] vs. 57.8 nu, P = .04). The low-frequency component (0.04-0.15 Hz), a mixture of both vagal and sympathetic activity, was increased in the e-cigarette users vs. nonusers (mean, 52 nu vs. 39.9 nu; P = .03). The ratio of low frequency to high frequency, reflecting the cardiac sympathovagal balance, also was increased for e-cigarette users (mean, 1.37 vs. 0.85; P = .05).
E-cigarette users had increased oxidative stress as the LDL oxidizability was increased compared with nonusers (mean, 3,801 U vs. 2,413.3 U; P = .01). No significant associations were found between e-cigarette users and high-density antioxidant/anti-inflammatory capacity and paraoxonase-1 activity.
“Although data from e-cigarette users were not compared with those from smokers of combustible cigarettes, the results of Moheimani et al demonstrate that the use of e-cigarettes is not without consequence and might impose CV harm and increase CVD risk,” Aruni Bhatnagar, PhD, director of The Diabetes and Obesity Center at the University of Louisville School of Medicine, wrote in an accompanying editorial. “Nevertheless, changes in [heart rate variability] and [LDL] oxidizability are indirect indices of [CV] injury, and it remains unclear to what extent these changes represent an increase in CVD risk.”
In a press release, Joep Perk, MD, cardiovascular prevention spokesman for the European Society of Cardiology, said: “E-cigarettes are one of the tools we have in nicotine replacement therapy, but as clinicians we should be cautious of putting people on large amounts of central nervous system stimulant drugs. Other smoking cessation schemes, such as chewing gum or patches, always include the decision to taper off use and eventually stop. This is not, in general, the case with e-cigarettes, which tend to be seen as a replacement and not a weaning off nicotine addiction. ... This is an area where we need more knowledge. The more data we collect, the more it seems that nicotine replacement strategies that taper off and ultimately end nicotine use are the way to go.” – by Cassie Homer

No comments:

Post a Comment